Your browser doesn't support javascript.
Return on Investment of the COVID-19 Vaccination Campaign in New York City.
Sah, Pratha; Vilches, Thomas N; Moghadas, Seyed M; Pandey, Abhishek; Gondi, Suhas; Schneider, Eric C; Singer, Jesse; Chokshi, Dave A; Galvani, Alison P.
  • Sah P; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
  • Vilches TN; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
  • Moghadas SM; Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
  • Pandey A; Agent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
  • Gondi S; Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut.
  • Schneider EC; Brigham and Women's Hospital, Boston, Massachusetts.
  • Singer J; The Commonwealth Fund, New York, New York.
  • Chokshi DA; The National Committee for Quality Assurance, Washington, DC.
  • Galvani AP; New York City Department of Health and Mental Hygiene, New York, New York.
JAMA Netw Open ; 5(11): e2243127, 2022 Nov 01.
Article in English | MEDLINE | ID: covidwho-2127460
ABSTRACT
Importance New York City, an early epicenter of the pandemic, invested heavily in its COVID-19 vaccination campaign to mitigate the burden of disease outbreaks. Understanding the return on investment (ROI) of this campaign would provide insights into vaccination programs to curb future COVID-19 outbreaks.

Objective:

To estimate the ROI of the New York City COVID-19 vaccination campaign by estimating the tangible direct and indirect costs from a societal perspective. Design, Setting, and

Participants:

This decision analytical model of disease transmission was calibrated to confirmed and probable cases of COVID-19 in New York City between December 14, 2020, and January 31, 2022. This simulation model was validated with observed patterns of reported hospitalizations and deaths during the same period. Exposures An agent-based counterfactual scenario without vaccination was simulated using the calibrated model. Main Outcomes and

Measures:

Costs of health care and deaths were estimated in the actual pandemic trajectory with vaccination and in the counterfactual scenario without vaccination. The savings achieved by vaccination, which were associated with fewer outpatient visits, emergency department visits, emergency medical services, hospitalizations, and intensive care unit admissions, were also estimated. The value of a statistical life (VSL) lost due to COVID-19 death and the productivity loss from illness were accounted for in calculating the ROI.

Results:

During the study period, the vaccination campaign averted an estimated $27.96 (95% credible interval [CrI], $26.19-$29.84) billion in health care expenditures and 315 724 (95% CrI, 292 143-340 420) potential years of life lost, averting VSL loss of $26.27 (95% CrI, $24.39-$28.21) billion. The estimated net savings attributable to vaccination were $51.77 (95% CrI, $48.50-$55.85) billion. Every $1 invested in vaccination yielded estimated savings of $10.19 (95% CrI, $9.39-$10.87) in direct and indirect costs of health outcomes that would have been incurred without vaccination. Conclusions and Relevance Results of this modeling study showed an association of the New York City COVID-19 vaccination campaign with reduction in severe outcomes and avoidance of substantial economic losses. This significant ROI supports continued investment in improving vaccine uptake during the ongoing pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: North America Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article